Thereby, this wide cytoprotection agenda (i.e., the cytoprotective agents direct (epithelial) cell protection is transmitted from the stomach to offer a similar beneficial effect in other organ lesions (cytoprotection organoprotection)) [35,36,37,38,39,40,41,42], with application of BPC 157 therapy (for review, see [1,3,4,5,6,8,9,32,33,34,92]), might be distinctive and might overwhelm the focused background of the current pharmacotherapy
[4] [5] Maintenance therapy is typically 1 mg every 23 months for life
Information below is for educational purposes only and not medical advice
Therefore, a bypassing key, i.e., an activated azygos vein as a rescuing pathway, avoiding both the lung and liver and also noted in BuddChiari syndrome (i.e., suprahepatic occlusion of the inferior caval vein) (Gojkovic et al., 2020), combines the inferior caval vein and superior caval vein via direct blood delivery
Before using BPC-157, its essential to understand what it is, how it works, and its potential risks
In case of discomfort or adverse effects related to contact with the substance, consult a doctor
